Drug Profile
Melanoma vaccine - Targeted Genetics
Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Targeted Genetics
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Malignant melanoma
Most Recent Events
- 09 May 2019 C3J Therapeutics has merged with AmpliPhi Biosciences Corporation to form Armata Pharmaceuticals
- 25 Oct 2000 Discontinued-I for Malignant melanoma in USA (Unknown route)
- 21 Nov 1996 New profile